Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Xilio Therapeutics, Inc.
| Metric | Xilio Therapeutics, Inc. XLOHealthcare |
|---|---|
| Quality Score | 50 / 100 |
| Revenue (latest) | $44M |
| Net income (latest) | −$35M |
| Operating margin | −95.9% |
| Net margin | −80.1% |
| Return on equity | −99.3% |
| Return on assets | −22.6% |
| Return on capital (ROCE) | −42.7% |
| Debt / equity | 3.39× |
| Revenue growth (YoY) | 589.9% |
| Altman Z″ (distress) | -6.58 |
| Accruals / assets | −19.4% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.